Testing Two Implementation Strategies in Collecting ePRO Among Multiple Myeloma Patients EPRO4MM

What's the purpose of this trial?

This clinical trial evaluates satisfaction and engagement with a text messaging platform (TXT-Chatbot) compared to a patient portal system (MyChart/Patient Portal) for reporting symptoms among patients with multiple myeloma (MM). 

This trial is currently open and accepting patients.

What will happen during the trial?

PRIMARY OBJECTIVES:

I. To evaluate the patients' preference of TXT-Chatbot approach versus MyChart/Patient Portal approach, considering their demographic information.

II. To evaluate each patient's adherence to the approach of his/her own choice by examining their utilization of the ePRO.

SECONDARY OBJECTIVE:

I. To examine the usability and satisfaction of the two implementation approaches of each patient's choice.

EXPLORATORY OBJECTIVE:

I. To explore and measure any differences in patients' preference of TXT-Chatbot approach versus MyChart/Patient Portal approach, as well as the number of completed of ePRO responses, in the course of 6 months, reported between race (African American versus [vs.] Caucasian) and approaches (Chatbot vs. MyChart/Patient Portal).

OUTLINE: Patients are assigned to 1 of 2 groups.

GROUP I: Patients receive a text message notification and complete surveys through TXT-Chatbot once every two weeks (Q2W) for 6 months.

GROUP II: Patients receive an email notification and complete surveys through MyChart/Patient Portal Q2W for 6 months.

After completion of study intervention, patients are followed up for 30 days.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

* Diagnosis of MM
* Able to use TXT or have Internet access
* Can read and understand English
* If patients are undergoing an autologous stem cell transplant, they will be enrolled after their transplant

Exclusion Criteria:

* \< 18 years of age
* Cognitive impairment documented in the electronic medical record (EMR)

Additional Trial Information

Enrollment: 200 patients (estimated)

View More
Need Help?

Interested in joining or learning more about this trial?

(888) 828-2206

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Pennsylvania

Sidney Kimmel Cancer Center Thomas Jefferson University

Philadelphia, PA

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • Add this trial to your favorites keyboard_arrow_right

    If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message